In 2022, more than 78,000 new cases of tuberculosis (TB) were reported in Brazil, with an incidence of 36.3 cases per 100,000 inhabitants. According to researchers from the Regional Prospective Observational Research for Tuberculosis (RePORT)-Brazil consortium, the country could improve the control of this infection if all patients were subjected to a sensitivity test capable of early detection of resistance not only to rifampicin, but also to isoniazid, before starting treatment. A study by the consortium published this year in Open Forum Infectious Diseases found that monoresistance to isoniazid predicted unfavorable outcomes at the national level.

Detecting tuberculosis early could play a significant role in eradicating the world’s most deadly infectious disease. The World Health Organization says 1.5 million people die from this devastating disease each year.

Washington, D.C., March 27, 2024 — With resistance to chemical antibiotics on the rise, the world needs entirely new forms of antimicrobials. A new study published in Microbiology Spectrum, a journal of the American Society for Microbiology, shows that an enzymatic cocktail can kill a variety of mycobacterial species of bacteria, including those that cause tuberculosis. The research was carried out by scientists at Colorado State University and Endolytix Technologies.

In a recent study published in The Lancet Infectious Diseases, researchers assessed the global, national, and regional burden and trends in tuberculosis.

Collaborative research from Trinity and RCSI University of Medicine and Health Sciences is recently published in the European Journal of Pharmaceutical Sciences and marked World TB Day (24th March 2024).

A new way to classify tuberculosis (TB) that aims to improve focus on the early stages of the disease has been presented by an international team involving researchers at the University College London (UCL).

• Studying the safety, immunogenicity and efficacy of MTBVAC in the most populated country in the world and the one with the highest number of cases of this infectious disease is key to continue advancing in this vaccine.

• Bharat Biotech International Limited in collaboration with Biofabri have started a series of clinical trials to evaluate the safety, immunogenicity and efficacy of MTBVAC in India.

• MTBVAC is being developed for two purposes: as a more effective and potentially longer-lasting vaccine than BCG for newborns, and for the prevention of TB disease in adults and adolescents, for whom there is currently no effective vaccine.

Spain. 24 March 2024. MTBVAC, the Spanish tuberculosis vaccine, the first live attenuated vaccine of Mycobacterium tuberculosis isolated from a human, reaches a new milestone by starting clinical trials in India, the most populated country in the world and the one with the highest number of cases of this infectious disease. 

The dictionary aims to unify TB-related terminology and promote clearer communication by providing a common language for researchers, policy-makers, donors and affected communities.

What could cancer teach us about tuberculosis? That’s a question Meenal Datta has been chasing since she was a graduate student.